Centessa [CNTA] vs Praxis Precision [PRAX] Detailed Stock Comparison

Centessa Pharmaceuticals plc - ADR

NASDAQ
Loading...

Praxis Precision Medicines Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 17 vital metrics comparison: Centessa Pharmaceuticals plc - ADR wins in 7 metrics, Praxis Precision Medicines Inc. wins in 6 metrics, with 1 ties. Centessa Pharmaceuticals plc - ADR appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Centessa Pharmaceuticals plc - ADR Praxis Precision Medicines Inc. Better
Price-to-Book Ratio 11.18 9.46 Praxis Precision Medicines Inc.
Debt-to-Equity Ratio 22.47 0.01 Praxis Precision Medicines Inc.
PEG Ratio -20.83 -38.31 Centessa Pharmaceuticals plc - ADR
EV/EBITDA -28.57 -26.32 Praxis Precision Medicines Inc.
Profit Margin (TTM) 0.00% 0.00% Tie
Operating Margin (TTM) -1,384.61% 0.00% Praxis Precision Medicines Inc.
Return on Equity -42.55% -45.83% Centessa Pharmaceuticals plc - ADR
Return on Assets (TTM) -20.53% -28.69% Centessa Pharmaceuticals plc - ADR
Free Cash Flow (TTM) $-194.19M $-249.12M Centessa Pharmaceuticals plc - ADR
1-Year Return 220.84% 501.76% Praxis Precision Medicines Inc.
Price-to-Sales Ratio (TTM) 406.97 N/A N/A
Enterprise Value $5.92B $8.58B Praxis Precision Medicines Inc.
EV/Revenue Ratio 394.98 N/A N/A
Revenue per Share (TTM) $0 N/A N/A
Earnings per Share (Diluted) $-1.46 $-13.48 Centessa Pharmaceuticals plc - ADR
Beta (Stock Volatility) 1.26 2.97 Centessa Pharmaceuticals plc - ADR
Short % of Float 2.58% 14.21% Centessa Pharmaceuticals plc - ADR

Centessa Pharmaceuticals plc - ADR vs Praxis Precision Medicines Inc. Stock Performance Analysis

Loading Price Chart...

CNTA
PRAX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Centessa Pharmaceuticals plc - ADR0.10%0.15%0.43%40.54%52.05%67.83%
Praxis Precision Medicines Inc.-0.77%4.46%-22.78%-13.27%-4.29%-7.63%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Centessa Pharmaceuticals plc - ADR220.84%599.30%59.45%82.62%82.62%82.62%
Praxis Precision Medicines Inc.501.76%1,560.93%-17.42%-36.07%-36.07%-36.07%

Performance & Financial Health Analysis: Centessa Pharmaceuticals plc - ADR vs Praxis Precision Medicines Inc.

MetricCNTAPRAX
Market Information
Market Cap i$6.10B$9.60B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i2,970,350391,453
90 Day Avg. Volume i4,090,580416,321
Last Close$39.76$264.54
52 Week Range$12.05 - $40.26$37.19 - $366.52
% from 52W High-1.24%-27.82%
All-Time High$39.98 (Jun 02, 2026)$914.27 (Jan 04, 2021)
% from All-Time High-0.55%-71.07%
Growth Metrics
Quarterly Revenue GrowthN/AN/A
Quarterly Earnings GrowthN/A-1.00%
Financial Health
Profit Margin (TTM) i0.00%0.00%
Operating Margin (TTM) i-13.85%0.00%
Return on Equity (TTM) i-0.43%-0.46%
Debt to Equity (MRQ) i22.470.01
Cash & Liquidity
Book Value per Share (MRQ)$3.53$34.85
Cash per Share (MRQ)$1.91$21.52
Operating Cash Flow (TTM) i$-193,816,992$-249,068,000
Levered Free Cash Flow (TTM) i$-138,539,376$-146,253,744
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Centessa Pharmaceuticals plc - ADR vs Praxis Precision Medicines Inc.

MetricCNTA (Apr 26, 2026)PRAX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) iN/AN/A
Forward P/E i-20.83-38.31
PEG Ratio i-20.83-38.31
Price to Sales (TTM) i406.97N/A
Price to Book (MRQ) i11.189.46
Market Capitalization
Market Capitalization i$6.10B$9.60B
Enterprise Value i$5.92B$8.58B
Enterprise Value Metrics
Enterprise to Revenue i394.98N/A
Enterprise to EBITDA i-28.57-26.32
Risk & Other Metrics
Beta i1.262.97
Book Value per Share (MRQ) i$3.53$34.85

Financial Statements Comparison: Centessa Pharmaceuticals plc - ADR vs Praxis Precision Medicines Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricCNTA (2025)PRAX (2025)
Revenue/Sales i15.00M0
Cost of Goods Sold iN/AN/A
COGS % of Revenue i0.0%-
Gross Profit iN/AN/A
Gross Margin i0.0%-
Research & Development i172.22M267.12M
Operating Income (EBIT) i-207.69M-326.20M
Operating Margin i-1,384.6%-
EBITDA i-183.33M-326.06M
EBITDA Margin i-1,222.2%-
Pre-Tax Income i-195.71M-303.27M
Pre-Tax Income % of Revenue i-1,304.8%-
Income Tax i1.82MN/A
Income Tax % of Revenue i12.1%-
Net Income (Profit) i-197.53M-303.27M
Profit Margin i-1,316.9%-

Balance Sheet & Liquidity Metrics

MetricCNTA (2025)PRAX (2025)
Cash & Equivalents i61.30M357.33M
Total Current Assets i367.88M610.91M
Total Current Assets % of Revenue i2,452.5%-
Total Current Liabilities i42.94M59.77M
Total Current Liabilities % of Revenue i286.2%-
Long-Term Debt i117.67M0
Long-Term Debt % of Revenue i784.5%-
Total Shareholders Equity i526.86M878.14M
Retained Earnings i-1.19B-1.14B
Retained Earnings % of Revenue i-7,908.2%-
Property, Plant & Equipment i0415,000

Cash Flow Statement Comparison

MetricCNTA (2025)PRAX (2025)
Operating Cash Flow i-168.95M-257.32M
Operating Cash Flow % of Revenue i-1,126.3%-
Capital Expenditures i-371,000-56,000
Free Cash Flow i-194.19M-249.12M
FCF Margin i-1,294.6%-
Debt Repayment i0N/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricCNTAPRAX
Shares Short i3.47M3.95M
Short Ratio i0.739.07
Short % of Float i2.58%14.21%
Shares Outstanding i149.23M25.20M
Float Shares i97.86M25.78M
% Held by Insiders i0.47%0.40%
% Held by Institutions i95.86%106.12%
% Held by Public i3.67%-6.52%

Dividend Analysis & Yield Comparison: Centessa Pharmaceuticals plc - ADR vs Praxis Precision Medicines Inc.

MetricCNTAPRAX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A